Provenge (sipuleucel-T) is an autologous cellular immunotherapy, which involves removing immune cells from a patient's blood, priming them to recognise prostate cancer, and then returning them to ...

For decades, researchers have worked to create drugs that teach the immune system to kill cancer cells the way traditional ...

Cancer vaccines harness the power of the immune system to stop tumors in their tracks. They work a little differently than ...

It’s been 13 years since the FDA approved its first therapeutic vaccine – Dendreon Pharma’s Provenge (sipuleucel-T) for prostate cancer, which was not a commercial success – and since then ...